Evidence map›Paper›PMID 36429000›Full record

ArticleCells2022

Circular RNA hsa_circ_0051040 Promotes Hepatocellular Carcinoma Progression by Sponging miR-569 and Regulating ITGAV Expression.

Linling Ju, Min Yao, Rujian Lu, Yali Cao, Huixuan Wang, Liuxia Yuan, Feng Xiao, Jianguo Shao, Weihua Cai, Lin Chen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Linling JuMedical School of Nantong University, Nantong University, Nantong 226001, China.
Min YaoMedical School of Nantong University, Nantong University, Nantong 226001, China.ORCID 0000-0002-5473-0186
Rujian LuNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Yali CaoNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Huixuan WangNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Liuxia YuanNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Feng XiaoNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Jianguo ShaoNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Weihua CaiNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Lin ChenNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Zhaolian BianNantong Institute of Liver Disease, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong 226006, China.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence has demonstrated the roles of circular RNAs (circRNAs) in hepatocellular carcinoma (HCC); however, their roles in HCC need to be further studied. Through high-throughput human circRNA microarray analysis of HCC and adjacent normal tissues, we identified hsa_circ_0051040 as a novel candidate circRNA for the diagnosis and treatment of HCC. In this study, we found that hsa_circ_0051040 was overexpressed in HCC tissues and cell lines and that its expression was correlated with poor prognosis. Knockdown of hsa_circ_0051040 inhibited the migration, invasion, and proliferation of HCC cells in vitro and in vivo, whereas overexpression of hsa_circ_0051040 had the opposite effects. Moreover, our data demonstrated that hsa_circ_0051040 acted as a sponge for miR-569 to regulate ITGAV expression and induce EMT progression. Our findings indicated that hsa_circ_0051040 promotes HCC development and progression by sponging miR-569 to increase ITGAV expression. Thus, hsa_circ_0051040 is a good candidate as a therapeutic target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsCell ProliferationGene Expression Regulation, NeoplasticHumansRNA, CircularMicroRNAsMIRN-569 microRNA, humanRNA, CircularEMThepatocellular carcinomahsa_circ_0051040ITGAVmiR-569

Identifiers

PMID36429000
PMCPMC9688127
OpenAlexW4309004029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.